PT  - JOURNAL ARTICLE
AU  - Goutaki, Myrofora
AU  - Lam, Yin Ting
AU  - Anagiotos, Andreas
AU  - Armengot, Miguel
AU  - Burgess, Andrea
AU  - Campbell, Raewyn
AU  - Carlier, Mathilde
AU  - Caversaccio, Nathalie
AU  - Chadha, Neil K.
AU  - Demir, Berat
AU  - Dheyauldeen, Sinan Ahmed D.
AU  - Gunaydin, Onder
AU  - Harris, Amanda
AU  - Hayn, Isolde
AU  - Inal-Ince, Deniz
AU  - Levi, Eric
AU  - Fernandez, Trini Lopez
AU  - Lucas, Jane S.
AU  - Maitre, Bernard
AU  - Poirrier, Anne-Lise ML
AU  - Schofield, Lynne
AU  - Takeuchi, Kazuhiko
AU  - van Gogh, Christine
AU  - Wolter, Nikolaus E.
AU  - Papon, Jean-François
TI  - Definition of sinonasal and otologic exacerbation in patients with primary ciliary dyskinesia - an expert consensus
AID  - 10.1101/2024.03.08.24303910
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.03.08.24303910
4099  - http://medrxiv.org/content/early/2024/03/09/2024.03.08.24303910.short
4100  - http://medrxiv.org/content/early/2024/03/09/2024.03.08.24303910.full
AB  - Background Recurrent infections of the nose, sinuses, and ears are common problems for people with primary ciliary dyskinesia (PCD). While pulmonary exacerbations in PCD are defined, there is no definition for Ear-Nose-Throat (ENT) exacerbations, a potential outcome for research and clinical trials.Methods We set up an expert panel of 24 ENT specialists, respiratory physicians, other healthcare professionals, and patients to develop consensus definitions of sinonasal and otologic exacerbations in children and adults with PCD for research settings. We reviewed the literature and used a modified Delphi approach with four electronic surveys.Results Both definitions are based on a combination of major and minor criteria, requiring three major or two major and at least two minor criteria each. Major criteria for a sinonasal exacerbation are: 1) reported acute increase in nasal discharge or change in colour; 2) reported acute pain or sensitivity in the sinus regions; 3) mucopurulent discharge on examination. Minor criteria include: reported symptoms; examination signs; doctoŕs decision to treat; improvement after at least 14-days. Major criteria for the otologic exacerbation are: 1) reported acute ear pain or sensitivity, 2) reported acute ear discharge, 3) ear discharge on examination, 4) signs of otitis media in otoscopy. Minor criteria are: reported acute hearing problems; signs of acute complication; doctoŕs decision to treat.Conclusion These definitions might offer a useful outcome measure for PCD research in different settings. They should be validated in future studies and trials together with other potential outcomes, to assess their usability.Competing Interest StatementNo potential conflict of interest relevant to this article was reported. JF Papon reports personal fees from Sanofi, GSK, Medtronic and ALK outside the submitted work. AL Poirrier received speaker honorarium from GSK outside the submitted work.Funding StatementThe study was supported by a Swiss National Science Foundation Ambizione fellowship (PZ00P3_185923) granted to M Goutaki. Several authors participate in the BEAT-PCD clinical research collaboration, co-chaired by M Goutaki and supported by the European Respiratory Society, and many centres participate in the ERN-LUNG (European Reference Network on rare respiratory diseases) PCD core.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Delphi surveys were part of achieving consensus among the research team of this manuscript. The process does not fall under the Human Research Act and does not require ethical approval. All participants joined the project and completed the electronic Delphi surveys on a voluntary basis.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes